Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal ...

Katherine McDaniel, MD, discusses fertility preservation options for patients facing a cancer diagnosis and how the landscape has changed over the past two decades.

In an interview with Targeted Oncology, Jacob Sands, MD, medical oncologist at Dana-Farber Cancer Institute, discusses the ...

A recent trial reveals metformin does not enhance survival in metastatic prostate cancer but offers significant metabolic ...

An expert discusses the multifaceted nature of CAR T-cell therapy for relapsed/refractory (R/R) large B-cell lymphoma (LBCL), emphasizing the need for early multidisciplinary coordination to address ...

Durvalumab's breakthrough therapy designation offers hope for improved outcomes in early-stage gastric and GEJ cancers, potentially transforming treatment strategies.

An expert discusses the evolving management of relapsed/refractory (R/R) large B-cell lymphoma (LBCL), illustrating how CAR T ...

FDA issued CRLs for RP1 and glofitamab; CB-010 shows promise in lymphoma; osimertinib plus chemo extends NSCLC survival; and ...

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited ...

John Burke, MD, discusses his editor-in-chief column from the July 2025 issue of Targeted Therapies in Oncology.

John M. Burke, MD, discusses the FDA ODAC's decision on the use of daratumumab in high-risk smoldering multiple myeloma and ...